| Management of trastuzumab-related cardiac dysfunction. | |
| | |
MedLine Citation:
|
PMID: 20728700 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Trastuzumab is the standard of care for the treatment of patients with ERB2-positive breast cancer. In a minority of patients, trastuzumab is associated with an increased incidence of cardiac dysfunction that ranges from asymptomatic decreases in left ventricular ejection fraction to symptomatic heart failure. In trials in the adjuvant setting, the difference in the incidence of cardiac events between the control and trastuzumab-containing arms was less than 4%. The baseline evaluation and oncologic setting (adjuvant versus metastatic disease) drive algorithms for the cardiac monitoring and management of these patients. When a patient develops documented left ventricular dysfunction, standard treatments for the management of heart failure should be prescribed. Trastuzumab cardiac dysfunction is an important clinical entity that can be managed effectively and individualized to maximize the cancer treatment benefit and minimize the risk and consequences of cardiac dysfunction. |
| | |
Authors:
|
Joseph R Carver |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Progress in cardiovascular diseases Volume: 53 ISSN: 1873-1740 ISO Abbreviation: Prog Cardiovasc Dis Publication Date: 2010 Sep-Oct |
Date Detail:
|
Created Date: 2010-08-23 Completed Date: 2010-09-27 Revised Date: 2013-05-08 |
Medline Journal Info:
|
Nlm Unique ID: 0376442 Medline TA: Prog Cardiovasc Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 130-9 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Abramson Cancer Center of The University of Pennsylvania, 1600 Penn Tower, Philadelphia, PA 19104, USA. jrc@mail.med.upenn.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / adverse effects* Antibodies, Monoclonal, Humanized Antineoplastic Agents / adverse effects* Breast Neoplasms / drug therapy*, pathology Female Heart Failure / chemically induced, diagnosis, physiopathology, therapy* Humans Risk Assessment Ventricular Dysfunction, Left / chemically induced, diagnosis, physiopathology, therapy* Ventricular Function, Left / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; P188ANX8CK/trastuzumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of biomarkers in chemotherapy-induced cardiotoxicity.
Next Document: Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected?